Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus
- 6 June 2004
- journal article
- research article
- Published by Springer Nature in Nature Neuroscience
- Vol. 7 (7) , 697-698
- https://doi.org/10.1038/nn1262
Abstract
In hippocampal pyramidal cells, a rise in Ca2+ releases endocannabinoids that activate the presynaptic cannabinoid receptor (CB1R) and transiently reduce GABAergic transmission—a process called depolarization-induced suppression of inhibition (DSI). The mechanism that limits the duration of endocannabinoid action in intact cells is unknown. Here we show that inhibition of cyclooxygenase-2 (COX-2), not fatty acid amide hydrolase (FAAH), prolongs DSI, suggesting that COX-2 limits endocannabinoid action.Keywords
This publication has 13 references indexed in Scilit:
- Modulation of anxiety through blockade of anandamide hydrolysisNature Medicine, 2002
- Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoidsProgress in Neurobiology, 2002
- A role for endocannabinoids in indomethacin-induced spinal antinociceptionEuropean Journal of Pharmacology, 2002
- Brain monoglyceride lipase participating in endocannabinoid inactivationProceedings of the National Academy of Sciences, 2002
- Pharmacological Activity of Fatty Acid Amides Is Regulated, but Not Mediated, by Fatty Acid Amide Hydrolase in VivoThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Oxygenation of the Endocannabinoid, 2-Arachidonylglycerol, to Glyceryl Prostaglandins by Cyclooxygenase-2Journal of Biological Chemistry, 2000
- Enzymes of porcine brain hydrolyzing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid receptorsBiochemical Pharmacology, 1999
- Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amidesNature, 1996
- COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex.Proceedings of the National Academy of Sciences, 1996
- Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonistBiochemical Pharmacology, 1993